Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 193

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 193
---
                                     |
| Vitamin             
 B12                 |     | An                                                                                                                                      
 essential dietary nutrient that the body needs daily in small amounts to function and stay healthy. Vitamin B12 helps make red blood    
 cells, DNA, RNA, energy, and tissues, and keeps nerve cells healthy. It is found in liver, meat, eggs, poultry, shellfish, milk,        
 and milk products. Chronic lack of vitamin B12 can result in anemia and central nervous system problems.                                |

| 95 |

<div align='center'>INDEX TO FINANCIAL STATEMENTS

bioAffinity Technologies, Inc.

Index to the Consolidated Financial Statements</div>

| Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 100)                                                                
 Consolidated Balance Sheets as of December 31, 2024 and 2023                                                                              
 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023                                                      | F-2 
 F-3 
 F-4 |
|:------------------------------------------------------------------------------------------------------------------------------------------|:----|
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023                                                      | F-6 |
| Notes to Consolidated Financial Statements                                                                                                | F-7 |

| F-1 |

<div align='center'>Report of Independent Registered Public Accounting Firm</div>

To the Board of Directors and Stockholders of

bioAffinity Technologies, Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of bioAffinity Technologies, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with principles generally accepted in the United States of America.

Substantial Doubt Regarding the